Broad Institute

JUNE 27, 2024

To deliver CHARM throughout the brain, the team collaborated with scientists in the lab of Ben Deverman , senior director of vector engineering at the Broad and a co-author of the study. They used an engineered adeno-associated virus (AAV) that crosses the blood-brain barrier after intravenous administration.

Disease 142

Disease Therapies Clinical Trials Engineering 142

Codon

SEPTEMBER 29, 2024

On the surface, they hadn't deviated much from the early 2020s: a virus infected a cell and released the genetic therapy hidden within. Dozens of diverse chemical markers and de novo , evolutionary distinct proteins littered the virus' surface, indicating a previously unseen biological logic.

Engineering 141

Engineering Virus DNA Therapies 141

Broad Institute

JULY 11, 2024

Targeted drug treatment leads tumor cells to imitate viral infection By Ari Navetta July 11, 2024 Breadcrumb Home Targeted drug treatment leads tumor cells to imitate viral infection Exploiting "viral mimicry," mIDH1 inhibitors trick tumors into thinking they are infected with a virus.

Treatment 72

Treatment Immune Response Drugs Virus 72

Drug Target Review

JANUARY 15, 2024

Each T cell expresses a TCR specific for an HLA‑presented peptide signal, and when that signal is detected a T cell expressing the relevant TCR can launch a complex array of immune effector responses that can suppress or destroy tumours or virus-infected cells. Many potential candidate antigens are under consideration.

Engineering 110

Engineering DNA Virus Immune Response 110

Drug Target Review

DECEMBER 28, 2023

These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response. Recognition of bacteria, viruses and fungal invaders as ‘foreign’ makes sense, but how does the immune system recognise cancer cells as a threat?

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

Drug Target Review

SEPTEMBER 11, 2023

This sugar-coated mucin binding to checkpoint receptors signals that the cancer cell poses no threat, consequently blocking the immune response. Tender elaborated that these results in immune cells ignoring the cancer rather than eliminating it, as they normally would.

Immune Response 116

Immune Response Research Engineering Virus 116

The Pharma Data

AUGUST 15, 2021

Melody Swartz, Jeffrey Hubbell and colleagues had previously developed a vaccine delivery tool called polymersomes – self-assembling, spherical nanoparticles that can encapsulate antigens and adjuvants (helper molecules that boost the immune response) and then release them inside immune cells.

Vaccine 52

Vaccine Virus Immune Response Clinical Trials 52

PLOS: DNA Science

OCTOBER 12, 2023

Can they deliver healing genes without triggering an overactive immune response? The details are disturbingly reminiscent of the famous case of Jesse Gelsinger , who died from a ferocious immune response to experimental gene therapy in September 1999. An immune response is two-tiered.

Therapies 69

Therapies Immune Response DNA Virus 69

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 128

Therapies Virus DNA Clinical Trials 128

Broad Institute

AUGUST 7, 2023

Related people Paul Blainey Nir Hacohen A signaling protein known as STING is a critical player in the human immune system, detecting signs of danger within cells and then activating a variety of defense mechanisms.

Regulations 91

Regulations Clinical Trials Engineering Science 91

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. About Novavax. Novavax, Inc.?(Nasdaq: Novavax Forward Looking Statements.

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

The Pharma Data

AUGUST 9, 2021

The pre-clinical animal trials of the intranasal vaccine showed a reduction in both the impact of the disease itself and transmission of the virus. This should prevent both clinical disease and virus transmission, to halt the spread of the COVID-19 pandemic.

Vaccine 52

Vaccine Virus Immune Response Disease 52

NIH Director's Blog: Drug Development

FEBRUARY 1, 2022

The decoy is a specially engineered protein particle that mimics the 3D structure of the ACE2 receptor , a protein on the surface of our cells that the virus’s spike proteins bind to as the first step in causing an infection. In the lab, it also appeared to neutralize the virus as well as monoclonal antibodies used to treat COVID-19.

Virus 52

Virus Clinical Trials Engineering Treatment 52

Drug Target Review

FEBRUARY 7, 2024

We had built a machine learning classifier that has been trained to identify amino acid sequences that have the potential to mimic ‘host defense peptides’ from the human innate immune system. Such peptides play a critical role in the machinery for amplifying innate immune responses. This work can potentially help with that also.

RNA 69

RNA Virus Immune Response Engineering 69

Drug Target Review

OCTOBER 2, 2024

Tissue engineering techniques using induced pluripotent stem cells (iPSC), which are differentiated into cardiomyocytes, are being developed to create functional cardiac tissues from patient-derived cells. While commonly used, AAVs have limitations, including immune reactions and difficulties with re-dosing due to pre-existing antibodies.

Therapies 98

Therapies Disease Engineering RNA 98

The Pharma Data

DECEMBER 20, 2020

BT-001 is a best-in-class oncolytic Vaccinia virus. platform and its patented large-capacity VV cop TK-RR- oncolytic virus, which has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR ® /F.I.R.S.T LUND, Sweden and STRASBOURG, France , Dec.

Virus 40

Virus Trials Clinical Trials Clinical Development 40

The Pharma Data

SEPTEMBER 30, 2021

That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. Breathe in, exhale.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

DECEMBER 10, 2020

In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

JUNE 1, 2022

Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the lungs, new research in mice suggests. Previous research has shown that caspase 11 in mice has many of the same immune-response functions as caspase 4 in humans.

Immune Response 52

Immune Response Virus Engineering Disease 52

The Pharma Data

NOVEMBER 9, 2020

NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. In preclinical trials, NVX-CoV2373 demonstrated induction of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

Broad Institute

AUGUST 11, 2022

In the new study, they homed in on a handful of these genes encoding enzymes that are members of the STAND ATPase family of proteins, which in eukaryotes are involved in the innate immune response. The cells underwent a dramatic defensive response and survived. The finding was striking and unprecedented.

DNA 52

DNA Virus Immune Response Bioinformatics 52

Drug Target Review

DECEMBER 5, 2024

2,3 Engineering both the capsid and DNA cargo improves the safety and efficacy of rAAV vectors and expands their clinical applications. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Adeno-associated virus-based gene therapy for lifelong correction of genetic disease. Labcompare. 2024;9(1):78.

Therapies 52

Therapies Virus DNA Compliance 52

The Pharma Data

NOVEMBER 30, 2020

About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. is undertaking clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.

Clinical Development 52

Clinical Development Vaccine Clinical Trials Immune Response 52

Advarra

JANUARY 11, 2024

After injection of such a vaccine, the mRNA instructs cells to produce proteins designed to stimulate an immune response against these same protein targets when they show up in viruses or in tumor cells. Adoptive T Cell Therapies Adoptive T cell therapy is another form of cancer treatment leveraging the patient’s immune system.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

Codon

DECEMBER 12, 2024

It would also be undetectable by key parts of the human immune system. Some scientists even think it had a virus defense system; “researchers say LUCA likely housed 19 CRISPR genes, which bacteria use to slice up viral threats,” reports Quanta Magazine.

RNA 102

RNA DNA Vaccine Virus 102

The Pharma Data

JUNE 25, 2021

“These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus. Variant Virus Strains. It was generally well-tolerated and elicited robust antibody response in Phase 1/2 clinical testing. against the original virus strain, 86.3%

Vaccine 40

Vaccine Trials Disease Immune Response 40

The Pharma Data

JANUARY 11, 2021

Upon binding, the antibodies block the spike protein from interacting with ACE2 and thereby prevent virus-induced cell-killing, also known as cytopathic effect. Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies.

Licensing 52

Licensing Licensing Therapies Engineering 52

The Pharma Data

AUGUST 22, 2021

Many of the elderly patients who survived the virus were poor: not exactly the demographic you would expect to fare well in a health crisis. This is how many medical studies begin, said biomedical engineering professor Phil Bourne, who serves as founding dean for the School of Data Science.

Doctors 52

Doctors Drugs Immune Response Virus 52

The Pharma Data

JANUARY 22, 2021

iosBio has claimed the OraPro platform enables oral delivery of thermally-stable, viral vector vaccines, which are engineered to withstand temperatures of up to 50°C. Novavax’s vaccine is a recombinant protein vaccine adjuvanted with Novavax’s nanoparticle technology, Matrix-M, which enhances immune response in recipients.

Vaccine 52

Vaccine Immune Response Government RNA 52

Codon

APRIL 30, 2023

Read more at Nature Biotechnology ( Similar paper at Nature Biomedical Engineering.) But now, their engineered brethren can live about 82 percent longer. Often, when we engineer a cell, we only mess with the magnitude of an effect; this study suggests that we should think more about the timing, too. From Zhang et al.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

Read more at Nature Biotechnology ( Similar paper at Nature Biomedical Engineering.) But now, their engineered brethren can live about 82 percent longer. Often, when we engineer a cell, we only mess with the magnitude of an effect; this study suggests that we should think more about the timing, too. From Zhang et al.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 9, 2023

LanzaTech announced a partnership with H&M Move to convert factory carbon emissions into fabrics using engineered microbes. Sponge cells double in population quite quickly — around 40 minutes — and could be engineered to manufacture drugs. Read Biological Engineering *Self-healable spider dragline silk materials.

Therapies 52

Therapies RNA Engineering Vaccine 52

Codon

JULY 27, 2023

But for a recent paper out of Nanjing, China, researchers engineered another enzyme and showed that, when mixed with FAST-PETase, the two worked together to break down plastic twice as fast as the Texas enzyme alone. a lower risk of immune responses. They don’t always break down PET into a form that is easily recycled.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

But for a recent paper out of Nanjing, China, researchers engineered another enzyme and showed that, when mixed with FAST-PETase, the two worked together to break down plastic twice as fast as the Texas enzyme alone. a lower risk of immune responses. They don’t always break down PET into a form that is easily recycled.

Therapies 52

Therapies RNA DNA Engineering 52

The Pharma Data

DECEMBER 27, 2020

It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory diseases. Transgene and BioInvent International received regulatory approval in Belgium for a Phase I/IIa trial of oncolytic Vaccinia virus BT-001. platforms and the human GM-CSF cytokine.

Trials 52

Trials Clinical Trials Therapies RNA 52

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. About TNX-1800.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Vaccine 40

Vaccine Trials FDA Clinical Trials 40